About half of HER2‐positive BCs also express hormone receptors (HRs).8 The coexistence of both estrogen receptors (ER) and progesterone receptors (PgR) expression and overexpression/amplification of HER2 is the hallmark of the subgroup called “triple positive” (TP) breast cancer. This evidence concerns the gene PGR and breast carcinoma.